Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study of Surufatinib in Refractory Metastatic G3 Neuroendocrine Tumors

NCT05973968 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT05973968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05973968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study of Surufatinib in Refractory Metastatic G3 Neuroendocrine Tumors
Lead sponsor
Qilu Hospital of Shandong University
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2023
Completion date
June 30, 2025
Enrollment
32 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumor grade 3